A PARP inhibitors in the treatment of breast cancer - A Review of literature
Introduction Breast cancer is the most common malignancy in women in developed countries. It also occurs in men. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2024-11-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/56024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846156351139479552 |
|---|---|
| author | Jagoda Niewiadomska Borys Bondos Aleksandra Stępień Alicja Paluch Jakub Skrzypek Aleksandra Niekra Łukasz Fussek Robert Kochan Ewelina Wieczorek Kacper Lee |
| author_facet | Jagoda Niewiadomska Borys Bondos Aleksandra Stępień Alicja Paluch Jakub Skrzypek Aleksandra Niekra Łukasz Fussek Robert Kochan Ewelina Wieczorek Kacper Lee |
| author_sort | Jagoda Niewiadomska |
| collection | DOAJ |
| description |
Introduction
Breast cancer is the most common malignancy in women in developed countries. It also occurs in men. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for this disease. The use of PARP inhibitors in the treatment of breast cancer has shown good results, so in this article we have done a review of the results of various studies on this topic. [1] In this review, the results of studies on the use of various PARP inhibitors in breast cancer of different hormonal status are presented.
Purpose
This article aims to give you an overview of the trials that have looked at the effects of different PARP inhibitors in the treatment of breast cancer. PARP inhibitors are a relatively new cancer therapy with good results, so it is important to pay attention.
State of Knowledge
In this article, I used the PubMed database and considered papers from the last 15 years, but most of the information in this review comes from papers published after 2020. I have also taken into account the recommendations of the FDA and the European Medicines Agency on the use of PARP inhibitors.
Conclusions
PARP inhibitors have shown significant effects on breast cancer outcomes. The differences in outcomes depending on the type of cancer, the PARP inhibitor used, and the previous therapies used in a given patient tell us how important it is to individualize therapy in oncology. The findings of the studies presented in this review also point to the need for further research that could focus on identifying patients who may best benefit from treatment with PARP inhibitors, as well as studying synergistic effects in combination with other forms of therapy, such as immunotherapy or chemotherapy. The changes in treatment outcomes that these drugs can bring underscore the importance of exploring new therapeutic strategies in oncology.
|
| format | Article |
| id | doaj-art-e27df600cf2e4d0cba64ee5f03e9324a |
| institution | Kabale University |
| issn | 2391-8306 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-e27df600cf2e4d0cba64ee5f03e9324a2024-11-26T08:02:00ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062024-11-017110.12775/JEHS.2024.71.56024A PARP inhibitors in the treatment of breast cancer - A Review of literatureJagoda Niewiadomska0Borys Bondos1Aleksandra Stępień2Alicja Paluch3Jakub Skrzypek4Aleksandra Niekra5Łukasz Fussek6Robert Kochan7Ewelina Wieczorek8Kacper Lee9Uniwersytet Medyczny w LublinieMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, PolandMedical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, Poland Introduction Breast cancer is the most common malignancy in women in developed countries. It also occurs in men. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for this disease. The use of PARP inhibitors in the treatment of breast cancer has shown good results, so in this article we have done a review of the results of various studies on this topic. [1] In this review, the results of studies on the use of various PARP inhibitors in breast cancer of different hormonal status are presented. Purpose This article aims to give you an overview of the trials that have looked at the effects of different PARP inhibitors in the treatment of breast cancer. PARP inhibitors are a relatively new cancer therapy with good results, so it is important to pay attention. State of Knowledge In this article, I used the PubMed database and considered papers from the last 15 years, but most of the information in this review comes from papers published after 2020. I have also taken into account the recommendations of the FDA and the European Medicines Agency on the use of PARP inhibitors. Conclusions PARP inhibitors have shown significant effects on breast cancer outcomes. The differences in outcomes depending on the type of cancer, the PARP inhibitor used, and the previous therapies used in a given patient tell us how important it is to individualize therapy in oncology. The findings of the studies presented in this review also point to the need for further research that could focus on identifying patients who may best benefit from treatment with PARP inhibitors, as well as studying synergistic effects in combination with other forms of therapy, such as immunotherapy or chemotherapy. The changes in treatment outcomes that these drugs can bring underscore the importance of exploring new therapeutic strategies in oncology. https://apcz.umk.pl/JEHS/article/view/56024PARP inhibitorsBreast cancerbreast cancer treatment |
| spellingShingle | Jagoda Niewiadomska Borys Bondos Aleksandra Stępień Alicja Paluch Jakub Skrzypek Aleksandra Niekra Łukasz Fussek Robert Kochan Ewelina Wieczorek Kacper Lee A PARP inhibitors in the treatment of breast cancer - A Review of literature Journal of Education, Health and Sport PARP inhibitors Breast cancer breast cancer treatment |
| title | A PARP inhibitors in the treatment of breast cancer - A Review of literature |
| title_full | A PARP inhibitors in the treatment of breast cancer - A Review of literature |
| title_fullStr | A PARP inhibitors in the treatment of breast cancer - A Review of literature |
| title_full_unstemmed | A PARP inhibitors in the treatment of breast cancer - A Review of literature |
| title_short | A PARP inhibitors in the treatment of breast cancer - A Review of literature |
| title_sort | parp inhibitors in the treatment of breast cancer a review of literature |
| topic | PARP inhibitors Breast cancer breast cancer treatment |
| url | https://apcz.umk.pl/JEHS/article/view/56024 |
| work_keys_str_mv | AT jagodaniewiadomska aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT borysbondos aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT aleksandrastepien aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT alicjapaluch aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT jakubskrzypek aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT aleksandraniekra aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT łukaszfussek aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT robertkochan aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT ewelinawieczorek aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT kacperlee aparpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT jagodaniewiadomska parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT borysbondos parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT aleksandrastepien parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT alicjapaluch parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT jakubskrzypek parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT aleksandraniekra parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT łukaszfussek parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT robertkochan parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT ewelinawieczorek parpinhibitorsinthetreatmentofbreastcancerareviewofliterature AT kacperlee parpinhibitorsinthetreatmentofbreastcancerareviewofliterature |